B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

NCT05296161 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

296

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Ocrelizumab

Sponsor

Amsterdam UMC, location VUmc